Cannabidiol in arthritis and joint pain: exploratory cross-sectional study

Introduction and clinical context

The study Cannabidiol in arthritis and joint pain: exploratory cross-sectional study (PubMed · 2022) is part of the scientific research on the use of cannabinoids in arthritis and rheumatology.

In rheumatic diseases — such as rheumatoid arthritis and osteoarthritis —, chronic joint pain and inflammation motivate the study of cannabinoids. Pioneering trials with nabiximols and studies with CBD report an analgesic effect and an improvement in physical function and sleep in some patients. The evidence is preliminary and use should complement — not replace — the baseline rheumatological treatment.

Understanding what science shows about the use of cannabinoids in arthritis and rheumatology helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This scientific review gathered and critically appraised the available literature on the topic. Reported improvement in pain (83%), physical function (66%) and sleep quality (66%) with CBD in arthritis. As a synthesis of multiple studies, it offers a more robust picture than isolated reports, though it depends on the quality of the included works. For clinical practice, syntheses like this help calibrate expectations and support clinical decisions.

Mechanism of action and safety

In rheumatic diseases, cannabinoids modulate pain through the endocannabinoid system and may have an anti-inflammatory effect, with CB2 receptors expressed in immune cells and synovial tissue. The most common adverse effects are dizziness, drowsiness and dry mouth, and THC can be psychoactive. Attention is recommended to interactions with analgesics and immunosuppressants. The therapy is studied as complementary and does not replace the baseline rheumatological treatment, such as disease-modifying antirheumatic drugs. Gradual titration and follow-up guide safe use.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (PubMed · 2022). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does cannabis help in arthritis?

Studies report pain relief and improved function and sleep; the evidence is preliminary and use is complementary.

Does it replace rheumatological treatment?

No. It complements the baseline treatment, under medical guidance.